Table 2 General characteristics of the participants for in vivo efficacy studies by region
Total | East | West | p-value* | ||
|---|---|---|---|---|---|
Age | mean (95% CI) | 31.6 (30.8, 32.3) | 35.2 (33.9, 36.5) | 30.0 (29.1, 30.9) | p < 0.001 |
range | (5, 80) | (8, 74) | (5, 80) | ||
missing | 61 | 7 | 54 | ||
Weight (kg) | mean (95% CI) | 52.9 (52.3, 53.5) | 55.2 (53.9, 56.4) | 52.3 (51.6, 53.0) | p < 0.001 |
range | (15, 92) | (18, 85) | (15, 92) | ||
missing | 223 | 164 | 59 | ||
Initial parasite | geometric mean (95% CI) | 17998 (16861, 19135) | 20478 (18189, 22766) | 16958 (15663, 18253) | p = 0.007 |
density | range | (520, 116960) | (560, 116000) | (520, 116960) | |
missing | 0 | 0 | 0 | ||
Sex | male (%) | 1071 (81.1) | 334 (85.2) | 737 (79.4) | p = 0.014 |
female (%) | 249 (18.9) | 58 (14.8) | 191 (20.6) | ||
missing | 7 | 0 | 7 |